Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human serum albumin/G-CSF fusion protein for prevention of chemotherapy-induced neutropenia in breast cancer
CTR20170687Phase 2Active
- Sponsor
- Tianjin PuYing Biotechnology
- Start
- Jul 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rHSA-GCSF in chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by Tianjin PuYing Biotechnology. Primary endpoint: Duration of grade IV neutropenia in cycle 1. Started Jul 2017; status: active.
02
Drugs
rHSA-GCSF
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on CTR20170687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170687.